Cytarabine + Fludarabine + Hydrocortisone Sodium Succinate + Imetelstat + Leucovorin Calcium + Methotrexate
Phase 1RecruitingDevelopment Stage
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
Feb 4, 2025 → Jun 30, 2026
About Cytarabine + Fludarabine + Hydrocortisone Sodium Succinate + Imetelstat + Leucovorin Calcium + Methotrexate
Cytarabine + Fludarabine + Hydrocortisone Sodium Succinate + Imetelstat + Leucovorin Calcium + Methotrexate is a phase 1 stage product being developed by Geron for Recurrent Childhood Acute Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06247787. Target conditions include Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06247787 | Phase 1 | Recruiting |
Competing Products
20 competing products in Recurrent Childhood Acute Myeloid Leukemia